

五鼎生技

APEXBIO

T a i w a n

2026 June

Disclaimer

- The information provided in this presentation, including views on future operations and development, is based on information currently available to the Company and reasonable expectations. Such information may contain forward-looking statements.
- Actual results of operations may differ from the contents of this presentation due to various risk factors, including but not limited to changes in market demand, industrial competition, supply chain fluctuations, raw material prices, exchange rate volatility, and regulatory adjustments.
- The Company undertakes no obligation to proactively update or revise the information disclosed in this presentation in the future.
- Financial data contained herein that has not been audited or reviewed by an independent auditor shall be subject to the information disclosed on the Market Observation Post System (MOPS).
- This presentation is intended for reference purposes in institutional investor conferences only and does not constitute any investment advice.

Company profile

- **TSEC 1733**
- **Industry** IVD Medical Device
- **Operation Locations**
 - .**Head quarter:** No. 7, Li-Hsin 5th Rd., Hsinchu Science Park, Hsinchu, Taiwan
 - .**Tao Yuan Factory:** No. 180, Lane 70, Wuqing Rd., Dayuan Dist., Taoyuan City, Taiwan
 - .**Suzhou Corp.:** Room 106, No.2, Kecheng Road, SIP, Suzhou, China
 - .**Omnis Health LLC** : 1736 River Hills Dr Suite 6, Nashville, TN 37210,USA
- **Started** 12/02/1997
- **IPO** 09/17/2001(1733 TSEC)
- **Capital** NTD 1 Billion
- **Chairman/CEO** Thomas Shen PhD
- **Employees** 664 people (upto 3/31/2026)
- **Company website:** www.apexbio.com

Milestone

1997-2001

1997 ApexBio set-up
1998 BGM FDA 510K approval
2001 Transit IPO listed to TSEC
2001 1st time FDA on-site inspection w/o 483

2002-2006

2002 ISO9001/13485 Notified
2003 CE IVDD notified
2004 Taiwan GMP notified
2006 2nd time FDA on-site inspection w/o 483

2007-2011

2009 Taoyuan factory set-up
2011 AEO certified by Customs Admin
2011 3rd time FDA on-site inspection w/o 483

2012-2016

2012 ApexBio Suzhou Corp se-up
2013 1st Taiwan MITTELSTAND Award from MOEA
2015 ISO14001/OHSAS18001 notified
2016 4th time FDA on-site inspection w/o 483

2017-2021

2017 Acquired Omnis Health LLC
2019 ISO45001:2018 notified

2022-2025

2023 MDSAP(USA/Canada/Brazil) notified
2024 MDSAP(USA/Canada/Brazil/Japan/Australia) notified
2024 Flu rapid test TFDA QMS notified
2025 MCS Eclipse PLUS 2025 Taiwan Excellence Award
2025 SA8000 CSR notified

Quality System

Region	The Authority	Regulatory compliance
Taiwan	TFDA	QMS
EU	CE	ISO 13485:2016 CE mark number:CE0197 EN ISO 15197:2015
USA	FDA	Quality System Regulation (21 CFR Part 820) 510K's on-site audit w/o 483 citations 2023 MDSAP (USA/Canada/Brazil)
China	NMPA	Medical Device Class II
Brazil	ANVISA	2017 passed on-site audit 2023 MDSAP (USA/Canada/Brazil)
Canada	Health Canada	2023 MDSAP (USA/Canada/Brazil)
Japan	PMDA	2024 MDSAP (USA/Canada/Brazil/Japan/Australia)
Australia	TGA	2024 MDSAP (USA/Canada/Brazil/Japan/Australia)

Product Series



自我血糖監測



居家健康管理



專業臨床試驗



定點照護檢驗

Product specification please refer to company website

Home diagnostics products



GCTU link



Hemoglobin



Glucose link



Uric Acid link



G/K POC wifi



Ketone link



Glucose POC link



Glucose link

New pipeline product

■ Rapid test

TFDA QMS passed

- COVID-19 Antigen Rapid Test Kit
- KP Rapid Test Kit
- Influenza Rapid Test Kit

Developing items:

- Vector-borne Disease Detection for Mosquito-borne Illnesses
- Economic Animal and Animal Epidemic Prevention Detection
- DOA



■ Home use CGM

五鼎捷測 JETest™

檢測市場、技術創新

公共健康與防疫、流行病監控、醫療機構專業診斷

開發項目



Global sales distribution

Territory	2024	2025	2026/1Q
America	39%	46%	39%
EU	48%	44%	53%
Asia	12%	9%	8%
Africa	1%	1%	0


Finance Performance

	2024	2025	2026/1Q
Revenue	1,852,211	1,944,907	519,723
Gross margin	521,342	538,741	175,664
Operation profit	128,464	140,726	87,211
Profit after tax	128,104	163,038	81,370
EPS	1.28	1.63	0.81
G/M ratio	28%	28%	34%
Shipped Meter Qty (kit)	1,368K	1,258K	281K
Shipped Strip Qty (pcs)	859M	914M	238M

Product ratio


2025

- BGM & A1C
- Non-BGM
- Electrode
- 其他(附件)



2026/1Q

- BGM & A1C
- Non-BGM
- Electrode
- Others



Non-BGM

Hemoglobin/Ketone/Uric Acid/Lactate/Cholesterol/
Pesticide quick check etc.

the 12th Corporate Governance Evaluation (2025年)

Category	Total number of indicators		Distribution weight		Points for satisfied indicators		Number of inapplicable indicators		AA/A+ Extra Credit Indicators		Scoring formula
	2024	2025	2024	2025	2024	2025	2024	2025	2024	2025	
Protecting Shareholder Rights and Interests and Treating Shareholders Equitably	14	11	0.19	0.16	13	10	0	0	1	0	14.55
Enhancing Board Composition and Operation	22	18	0.29	0.25	17	14	0	0	3	3	19.44
Increasing Information Transparency	13	7	0.17	0.10	10	5	0	0	1	1	7.14
Putting Corporate Social Responsibility into Practice	26	34	0.35	0.49	21	26	0	0	2	2	37.47
Others	2	2	-	-	-	-	-	-	-	-	78.6
Total											84.6

Ranking (SEC): 51%~65%

Industry Category: Market Capitalization Under NT\$5 Billion, ranking : 11% ~20%

Thank you

